- ISPOR-FDA Summit 2020
- ISPOR 2020
- ISPOR Asia Pacific 2020
- ISPOR Dubai 2020
- ISPOR Europe 2020
- ISPOR Europe 2019
- ISPOR Summit 2019
- ISPOR Latin America Summit 2019
- ISPOR Latin America 2019
- ISPOR 2019
- ISPOR Warsaw 2019
- ISPOR Europe 2018
- ISPOR Summit 2018
- ISPOR Dubai 2018
- ISPOR Asia Pacific 2018
- ISPOR 2018
- ISPOR Europe 2017
- ISPOR Latin America 2017
- ISPOR Asia Pacific 2016
- Abstract Information
- Submit Abstract
- Exhibits & Sponsorships
- Awards & Grants
- Recent Conferences
- Upcoming Conferences
Education & Training
- In-Person Training
- Introduction to Outcomes Research
- Introduction to Systematic Reviews & Meta-Analysis
- Systematic Review & Meta-Analysis: Applications
- Introduction to Pharmacoeconomics
- Cost-of-Illness/Cost-Estimation (COI/CE)
- Cost-Minimization/Cost-Consequence (CMA/CCA)
- Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA)
- Modeling Health Care Costs – Part I: Characteristics of Health Care Costs
- Modeling Health Care Costs – Part II: Methods and Guidelines for Estimating Health Care Costs
- Modeling Health Care Costs – Part III: Estimation from Censored Data
- Introduction to Budget Impact Analysis (BIA) - Part I
- Introduction to Budget Impact Analysis (BIA) - Part II
- Markov Model Toolkit: Concepts, Assumptions and Examples
- An Introduction to Choice-Based Conjoint Analysis (Discrete Choice Experiments)
- Health-Related Quality of Life (HRQOL) – Basics
- Patient Reported Outcomes: Analysis and Interpretation
- Patient Reported Outcomes: Instrument Development
- Item Response Theory: A Conceptual Introduction
- Preparing for Multinational Clinical Trials: Translation and Cultural Adaptations of PRO Measures
- Evidence Generation for Patient Reported Outcome (PRO) Label Claims (FDA Requirements)
- Intermediate Retrospective Observational Study - Propensity Scoring Methods
- Use of Public Survey Data in Health Outcomes Research
- Distance Learning
Outcomes research attempts to understand and explain the end results of health care interventions. The end results of health care can fall into a variety of classifications of morbidity and mortality. These outcomes may be clinical (e.g., infections), humanistic (e.g., functional status), or economic (e.g., associated costs). By linking health care to the appropriate outcomes, it is possible to value the impact of that care. Indeed, the selection and measurement of outcomes drives outcomes research.
Pharmacoeconomics is a branch of outcomes research that focuses on the impact of pharmaceuticals and pharmaceutical services on outcomes. Outcomes are the Pharmaco- part of Pharmacoeconomics (i.e., without outcomes, there is no Pharmacoeconomics). Thus, it is critical to understand and use the various measures that can assess the impact of health care.
Selection of outcomes used in pharmacoeconomics depends on a many factors. These include the perspective of the decision maker, the feasibility of collecting outcomes, and the link between intermediate measures and the ultimate desired outcomes.
This module will define outcomes, classify outcomes according to different typologies, and suggest strategies for choosing outcomes for pharmacoeconomics studies. The emphasis will not be on patient related outcomes, since they will be discussed in detail in another module. Rather, this module provides a broad introductory overview of all outcomes in pharmacoeconomics studies. This module is based upon more than 10 years of experience in teaching and consulting with students and pharmacists.
By the end of the Introduction to Outcomes Research module, you will be able to:
- Define and contrast outcomes, surrogates, and intermediate outcomes.
- Discuss different classification systems for characterizing health outcomes.
- Contrast the quality of outcomes collected from different sources and levels of evidence.
- List questions to consider in choosing outcomes data for Pharmacoeconomics studies.